Get the Stockscreener App
107.71
3.15%
3.29
Zimmer Biomet Holdings Inc stock is traded at $107.71, with a volume of 1.10M.
It is up +3.15% in the last 24 hours and up +11.59% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$104.42
Open:
$105.25
24h Volume:
1.10M
Relative Volume:
0.57
Market Cap:
$21.34B
Revenue:
$7.68B
Net Income/Loss:
$903.80M
P/E Ratio:
24.20
EPS:
4.45
Net Cash Flow:
$1.14B
1W Performance:
+4.83%
1M Performance:
+11.59%
6M Performance:
+2.75%
1Y Performance:
-5.03%
1-Day Range:
$104.85
$107.77
1-Week Range:
$101.79
$107.77
52-Week Range:
$89.24
$116.71
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
107.71 | 20.32B | 7.68B | 903.80M | 1.14B | 4.45 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Upgrade | Roth Capital | Neutral → Buy |
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Zimmer Biomet Holdings Inc. Inches Above Key Support — Safe to HoldJuly 2025 Action & AI Driven Price Forecasts - beatles.ru
Do Wall Street Analysts Like Zimmer Biomet Stock? - Barchart.com
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock - Yahoo Finance
North America Pectus Bar Market Forecast Report to 2031, - GlobeNewswire
North America Pectus Bar Market Forecast Report to 2031, with Leading Player Profiles for KLS Martin Group, Biotech, Zimmer Biomet Holdings, Ventura Medical Technologies, and MedXpert - Yahoo Finance
Should I hold or sell Zimmer Biomet Holdings Inc. nowJuly 2025 Selloffs & Accurate Entry and Exit Point Alerts - newsyoung.net
Monogram Technologies Announces Merger with Zimmer Biomet - MSN
Stock Analysis | Zimmer Biomet OutlookA Divergent Picture Between Strong Fundamentals and Weak Technicals - AInvest
Monogram Technologies Inc. SEC 10-Q Report - TradingView
Is Zimmer Biomet Holdings Inc. still a buy after recent gainsPortfolio Profit Report & Daily Technical Stock Forecast Reports - thegnnews.com
Zimmer Biomet Holdings: Unusual Items Mask Strong Profit Growth - AInvest
Published on: 2025-08-14 17:26:03 - beatles.ru
Zimmer Biomet’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Zimmer Biomet’s Strong Q2 Performance and Optimistic Outlook - The Globe and Mail
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term - Yahoo Finance
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q2 2025 Earnings Call Transcript - MSN
Zimmer Biomet Expects Strong Q2 Earnings, Raises Guidance on Robust Performance and Strategic Acquisitions - AInvest
Orthopedic Devices Company Evaluation Report 2024-2025 | Stryker, Zimmer Biomet, and Johnson & Johnson MedTech Lead Across Joint Replacement, Trauma, and Surgical Solutions - Yahoo Finance
Is Zimmer Biomet Holdings Inc. stock forming a cup and handleHigh Conviction Technical Setups - classian.co.kr
Needham Maintains a Neutral Stance on Zimmer Biomet Holdings (ZBH) - MSN
Zimmer (ZBH) Builds Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside - MSN
Zimmer Biomet (ZBH) Jumps After Raising 2025 Outlook on Strong Hip and Knee Sales—Is Momentum Sustainable? - simplywall.st
Zimmer Biomet Acquires Monogram Technologies, Boosting Robotics Growth Pipeline, but BofA Sees Limited Near-Term Upside - AInvest
Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest
What You Need To Know Ahead of Zimmer Biomet's Earnings Release - MSN
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up - MSN
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $96 to $138 - 富途牛牛
While shareholders of Zimmer Biomet Holdings (NYSE:ZBH) are in the red over the last five years, underlying earnings have actually grown - simplywall.st
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MSN
Zimmer Biomet Holdings Maintains Hold Rating Amid Volatility Concerns - AInvest
Zimmer Biomet Surges Despite 404th-Ranked Liquidity as Earnings Outperform and UBS Maintains Sell Rating - AInvest
UBS Raises Price Target for Zimmer Biomet Holdings (ZBH) to $96 | ZBH Stock News - GuruFocus
RBC Capital Raises Zimmer Biomet PT to $115, Maintains Outperform Rating - AInvest
UBS maintains Sell rating, raises Zimmer Biomet PT to $96 from $91. - AInvest
Morgan Stanley Raises Price Target on Zimmer Biomet to $100 From $95 - MarketScreener
Raymond James maintains Outperform rating on Zimmer Biomet with new PT of $113. - AInvest
Zimmer Biomet Holdings, Inc. shares fall 1.09% intraday as brokerages adjust price targets and global growth concerns persist. - AInvest
RBC Raises Price Target on Zimmer Biomet Holdings to $115 From $112, Keeps Outperform Rating - MarketScreener
Zimmer Biomet price target raised to $113 from $104 at Raymond James - TipRanks
UBS Hikes Price Target on Zimmer Biomet to $96 From $91, Maintains Sell Rating - MarketScreener
Bernstein raises Zimmer Biomet stock price target to $105 on improving outlook - Investing.com Canada
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $95 to $138 - 富途牛牛
Zimmer Biomet Boosts 2025 Outlook on Strong Portfolio Growth and Reduced Tariff Impacts - AInvest
Zimmer Biomet price target raised to $96 from $91 at UBS - TipRanks
Zimmer Biomet raises 2025 outlook amid strong portfolio growth - Yahoo Finance
Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained - TipRanks
Zimmer Biomet Q2 2025 net sales up 7% to USD 2.077B - Medical Buyer
Jefferies Adjusts Price Target on Zimmer Biomet to $110 From $103, Maintains Hold Rating - MarketScreener
Bernstein Adjusts Price Target on Zimmer Biomet to $105 From $100, Maintains Market Perform Rating - MarketScreener
JPMorgan Adjusts Price Target on Zimmer Biomet to $115 From $105, Maintains Overweight Rating - MarketScreener
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):